RT Journal Article
T1 Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)
A1 González Rincón, Julia
A1 Anguita Mandly, Eduardo Luis
A1 Córdoba, Raúl
A1 García Marco, José A.
AB Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in Western countries and is notable for its variable clinical course. This variability is partly reflected by the mutational status of IGHV genes. Many CLL samples have been studied in recent years by next-generation sequencing. These studies have identified recurrent somatic mutations in NOTCH1, SF3B1, ATM, TP53, BIRC3 and others genes that play roles in cell cycle, DNA repair, RNA metabolism and splicing. In this study, we have taken a deep-targeted massive sequencing approach to analyze the impact of mutations in the most frequently mutated genes in patients with CLL enrolled in the REM (rituximab en mantenimiento) clinical trial. The mutational status of our patients with CLL, except for the TP53 gene, does not seem to affect the good results obtained with maintenance therapy with rituximab after front-line FCR treatment.
PB PLOS
SN 1932-6203
YR 2021
FD 2021-09-10
LK https://hdl.handle.net/20.500.14352/115704
UL https://hdl.handle.net/20.500.14352/115704
LA eng
NO González-Rincón, J., Garcia-Vela, J. A., Gómez, S., Fernández-Cuevas, B., Nova-Gurumeta, S., Pérez-Sanz, N., Alcoceba, M., González, M., Anguita, E., López-Jiménez, J., González-Barca, E., Yáñez, L., Pérez-Persona, E., de la Serna, J., Fernández-Zarzoso, M., Deben, G., Peñalver, F. J., Fernández, M. C., de Oteyza, J. P., Andreu, M. Á., … García-Marco, J. A. (2021). Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM). PloS one, 16(9), e0257353. https://doi.org/10.1371/journal.pone.0257353
NO Plan Estatal de I+D+I 2008-2011Plan Estatal de I+D+I 2013-2016
NO Ministerio de Economía y Competitividad (España)
NO Comunidad Autónoma de Madrid
DS Docta Complutense
RD 6 abr 2025